tbuckley/cabot-search huggingface dataset:
p53 Gene Expression in Node-Positive Breast Cancer: Relationship to DNA Ploidy and Prognosis
Authors: J. M. Cunningham, J. N. Ingle, S. H. Jung, S. S. Cha, L. E. Wold, G. Farr, T. E. Witzig, J. E. Krook, H. S. Wieand, J. S. Kovach
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article p53 Gene Expression in Node-Positive Breast Cancer: Relationship to DNA Ploidy and Prognosis Get access J. M. Cunningham, J. M. Cunningham Department of Oncology, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar J. N. Ingle, J. N. Ingle Department of Oncology, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar S. H. Jung, S. H. Jung Department of Health Sciences, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar S. S. Cha, S. S. Cha Department of Health Sciences, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar L. E. Wold, L. E. Wold Department of Laboratory Medicine and Pathology, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Farr, G. Farr Ochsner Community Clinical Oncology Program (CCOP)New Orleans, La Search for other works by this author on: Oxford Academic PubMed Google Scholar T. E. Witzig, T. E. Witzig Department of Medicine, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar J. E. Krook, J. E. Krook Duluth Clinic CCOPDuluth, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar H. S. Wieand, H. S. Wieand Department of Health Sciences, Mayo FoundationRochester, Minn Search for other works by this author on: Oxford Academic PubMed Google Scholar J. S. Kovach J. S. Kovach Department of Oncology, Mayo FoundationRochester, Minn Correspondence to present address : J. S. Kovach, M.D., City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 910100269. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 24, 21 December 1994, Pages 1871–1873, https://doi.org/10.1093/jnci/86.24.1871 Published: 21 December 1994 Article history Received: 18 February 1994 Revision received: 16 August 1994 Accepted: 16 September 1994 Published: 21 December 1994
Abstract 3315: Malignant melanoma cells reciprocate aspects of the embryonic neural crest migration program to promote invasion and increased plasticity
Authors: Caleb M. Bailey, Jason A. Morrison, Paul M. Kulesa
Journal: Cancer Research (2012)

Abstract Melanocytes derive from a highly invasive, multipotent embryonic cell population known as the neural crest. It has been proposed that this ancestral relationship predisposes melanocytes to having metastatic characteristics following neoplastic transformation to melanoma. In support of this hypothesis, we have previously shown that aggressive melanoma cells transplanted into the chick embryonic neural crest microenvironment respond to neural crest signaling mechanisms by emigrating along defined host neural crest pathways. To evaluate whether melanoma cells usurp aspects of the neural crest program typically silenced in differentiated melanocytes, we have employed the chick embryo transplant model coupled with laser capture microdissection to perform an in vivo molecular analysis of more than 70 neural-crest-related genes. Transplanted cells included c8161 aggressive melanoma cells, a poorly aggressive isogenic counterpart termed c81-61, and primary human melanocytes. We demonstrate that all three cell types express many neural-crest-related genes, but that aggressive cells aberrantly express some genes typically lost during melanocyte differentiation. Furthermore, the analysis revealed a significant increase in the ability of aggressive melanoma cells to respond to changing microenvironments by altering gene expression signatures, while transplanted melanocytes appeared to actively suppress these pathways. This increased responsiveness may be attributed to the dynamic regulation of Eph receptor tyrosine kinases and their cognate ephrin ligands, many of which were differentially expressed in aggressive melanoma cells versus poorly aggressive melanoma or primary melanocytes. Thus, metastatic melanoma cells usurp portions of the neural crest program to promote increased invasiveness and plasticity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3315. doi:1538-7445.AM2012-3315
AT-03 * PHASE I TRIAL OF ENZASTAURIN (LY 317615) IN COMBINATION WITH CARBOPLATIN IN ADULTS WITH RECURRENT GLIOMA
Authors: P. Ambady, T. Kreisl, K. Warren, K. McNeill, H. Fine
Journal: Neuro-Oncology (2014)

BACKGROUND: Enzastaurin is a selective protein kinase-C β inhibitor with antiangiogenic activity. Preclinical studies support its potential efficacy in combination with carboplatin in high-grade glioma. METHODS: The objective of this open-label phase-I study in adults with refractory high-grade glioma was to determine the maximum tolerated dose, and describe pharmacokinetics of carboplatin in combination with enzastaurin. Patients were stratified based on antiepileptic medication [Group A= nEIAED, Group B = EIAED]. A lead in period with single agent enzastaurin was administered for 7 days (loading dose of 1125 mg Day 1 + 500 mg/d x 6d (Group A); 875 mg/d x 6d (Group B). Each subsequent 28-day-cycle consisted of carboplatin (AUC 3, 4, 5, or 6 Day 1) with enzastaurin (500-875 mg/d Day 1-28). Carboplatin was dose escalated on a 4 + 8 schema. Plasma samples for enzastaurin, its active metabolite-LY326020 and total-platinum were collected at various time points. Adverse events were monitored and graded using NCI CTCAE criteria version 3.0. RESULTS: Fifty-eight patients were accrued (43 Group A;15 Group B). 12 dose limiting toxicities (DLT) occurred in 11 patients (Group-A, 8; Group B, 3). These included lymphopenia (n = 5), deep-vein thrombosis (n = 2), and thrombocytopenia (n = 2). Multi-organ failure resulted in 1 study-related death in Group A. PK analyses were available for 32 patients. Lower area under the plasma concentration time curve ( AUCt), maximum (Cmax ), and average steady-state concentration (Cav,ss) for enzastaurin and LY326020 were noted in Group B. Total platinum exposures [AUC(0-∞)] were generally lower than the targeted AUC but increased with increasing dose, and no differences were observed when given with enzastaurin. CONCLUSION: The maximum tolerated dose of carboplatin in combination with enzastaurin was not reached prior to termination of the study for poor accrual. EIAEDs significantly decreased enzastaurin and its active metabolite. No significant pharmacokinetic interactions were noted between enzastaurin and carboplatin.
Abstract 5525: Influence of total dissected lymph node number on metastatic detection rate and survival in 10,382 esophageal cancer patients from the high incidence area for esophageal cancer in northern China
Authors: Li Dong Wang, Jin Cheng Dong, Peng Zhang, Fu You Zhou, Xue Min Li, Ai Li Li, Ai Fang Ji, Zhi Cai Liu, Xin Song, Xue Ke Zhao, Xian Zeng Wang
Journal: Cancer Research (2012)

Abstract Lymph node (LN) metastasis has been recognized as one of the most important factors for poor prognosis of esophageal cancer (EC). However, the influence of dissected LN number on metastatic detection rate and survival in EC has not been well documented. The present study was undertaken to correlate the total number of dissected LN, metastatic detection rate and survival on 10,382 EC patients. All the patients had been performed surgical treatment and confirmed as esophageal squamous cell carcinoma (ESCC) by histopathological examination. The patients were from Henan, Hebei and Shanxi provinces, the high incidence areas for EC in northern China, including 6,375 males with a mean age of 58±9 and 4,007 females with a mean age of 59±9. Of the patients, 2,714 cases have been followed up by interview at home until July, 2010. Eight EC groups had been classified based on the total number of dissected LN (1-3, 4-5, 6-7, 8-9, 10-11, 12-13, 14-16 and ≥17). The results showed that the positive metastatic detection rate apparently increased with the total extended dissected LN number (P&amp;lt; 0.05) until reaching the level with a total of 17 or more dissected LN. 5-year survival analysis showed that the patients without LN metastasis had a higher survival rate than those with LN metastasis in all seven groups (P&amp;lt;0.05) except the group with ≥17. Interestingly, the survival rate was similar in the group of ≥17 between the patients with positive or negative LN (P&amp;gt;0.05). We concluded that the total dissected LN number could affect the survival rate for EC and that a total of 10 to 16 dissected LN should be recommended for EC surgical treatment. (supported by Innovation Scientists and Technicians Troop Construction Projects of Henan Province). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5525. doi:1538-7445.AM2012-5525
EG-15 * THE METHYLATION STATUS OF MGMT IN MEDULLOBLASTOMA
Authors: Y. Shimizu, T. Kurimoto, A. Kondo, H. Arai
Journal: Neuro-Oncology (2014)

BACKGROUND: Medulloblastoma is a highly malignant brain tumor in childhood. Some studies reported that alkylating chemotherapeutic drugs are effective agents in the treatment of patients with medulloblastoma. O6-methylguanine-DNA methyltransferase (MGMT) is one of the DNA repair enzymes and plays a significant role in tumor resistance to alkylating agents. Low MGMT expression or MGMT promoter methylation have been found to be associated with favorable outcomes in malignant glioma patients treated with alkylating agents such as temozolomide. However, impact of MGMT status on clinical outcomes in medulloblastoma patients is not fully evaluated. OBJECTIVE: The objective of this study is to investigate the association between MGMT status and the response for chemotherapy in pediatric patients with medulloblastoma. METHODS: Patients with medulloblastoma treated at our institution between 1995 and 2012 were reviewed retrospectively. Relevant clinical information including current disease status, tumor response to chemotherapy was obtained from the hospital charts. To evaluate the MGMT status, we performed bisulfite sequencing analysis to determine the methylation status of the MGMT promoter. RESULTS: Tumor material and detailed clinical information were available in 22 patients. Of them, 13 patients were alive (11 in CR), seven died of disease and two were lost to follow up. Five patients were with dissemination at diagnosis. We succeeded to evaluate both the MGMT status of tumors and the number of methylation sites in MGMT promoter. CONCLUSIONS: We studied the prognostic value of MGMT promoter methylation in medulloblastoma children.
Adduction Contracture of the Thumb
Authors: J. Edward Flynn
Journal: New England Journal of Medicine (1956)

ADDUCTION contracture of the thumb presents a most serious disability of the hand. The thumb is useless as an opponent for the fingers, is unable to abduct and rotate and, in some cases, blocks flexion of the fingers. The hand is incapable of proper grasp, pinch and stereognosis. The proper mechanics of position of the thumb are crippled.Functional AnatomyThe thumb is controlled by 4 long and 6 short muscles arranged about its circumference and supplied by the radial, median and ulnar nerves. Roughly, the radial controls extension, the median flexion, and the ulnar adduction. No one muscle acts . . .
Abstract 2152: Paroxetine, a selective serotonin re-uptake inhibitor, induces growth inhibition and apoptosis in prostate cancer cells
Authors: Tadamasa Shibuya
Journal: Cancer Research (2011)

Abstract Introduction and Objective: Recently, neuroendocrine cells is suggested to be involved in prostate cancer (PC) progression through the secretion of a variety of neuroendocrine products, such as serotonin, which have mitogenic effects on adjacent cancer cells and thus can contribute to the androgen independent proliferation of PC cells. With having experience that a patient with hormone refractory prostate cancer responded to paroxetine, a selective serotonin re-uptake inhibitor (SSRI), in serum prostate specific antigen (PSA) level, we investigated the effect of paroxetine on the growth and apoptosis induction in PC cell lines. Methods: Paroxetine was administered to four patients with hormone refractory, metastatic PC and their serum PSA levels were determined. The effects of paroxetine on the growth and apoptosis induction in PC cell lines (PC3, DU145, 22RV1 and LNCaP) were confirmed. Cell growth inhibition was assessed in vitro by cell number count. The induction of apoptosis was examined by flow cytometry analysis and caspase activations were confirmed by western blot analysis. Results: Serum PSA levels decreased soon after the administration of paroxetine but increased again in all four patients but one in whom it decreased from 0.485 ng/ml to undetectable level (less than 0.008 ng/ml) for over three years. In vitro study, paroxetine inhibited cell growth in a dose and time dependent manner. The 50% inhibitory concentration (IC50 values) of paroxetine in PC3, 22RV1, DU145 and LNCaP cells were 38.8, 30.1, 35.9 and 21µM, respectively. Apoptosis induction following the treatment of paroxetine was revealed in prostate cancer cells by the increase of sub-G1 population in flow cytometry analysis and a cleavage of procaspase-3 in western blot analysis. Conclusions: A potent SSRI, paroxetine, induces growth inhibition and apoptosis in PC cells. These results suggest that SSRIs have the potential of anti-tumor effect against PC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2152. doi:10.1158/1538-7445.AM2011-2152
Resolution Rate of Acute Pulmonary Embolism in Man
Authors: James E. Dalen, John S. Banas, Harold L. Brooks, Gerald L. Evans, John A. Paraskos, Lewis Dexter
Journal: New England Journal of Medicine (1969)

In 15 patients with definite angiographic evidence of embolism involving both lungs, and treated with heparin or venous ligation or both, sequential studies showed only minimal angiographic and hemodynamic signs of resolution at seven days. By 10 to 21 days, pressures in the right side of the heart had decreased to near normal levels, and there was unmistakable angiographic evidence of resolution. Complete resolution, with normal angiograms and hemodynamics, was noted in three patients at 14, 15 and 34 days. In other patients angiographic and hemodynamic abnormalities persisted weeks after embolism.
Late Breaking News: Healy Sworn In as NIH Director
Authors: Cori Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Late Breaking News: Healy Sworn In as NIH Director Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 14, 17 July 1991, Page 995, https://doi.org/10.1093/jnci/83.14.995 Published: 17 July 1991
THE ROLE OF 18 F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN THE INVESTIGATION OF REGIONAL AORTIC INFLAMMATION IN PATIENTS WITH SUCCESSFULLY REPAIRED COARCTATION OF THE AORTA
Authors: Styliani V. Brili, Constantinos Anagnostopoulos, Evangelos Oikonomou, Nikoletta Pianou, Emmanouil Athanasiadis, Alexandros Georgakopoulos, Pavlos Kafouris, George Spyrou, Iosif Cutajar, Petros Nihoyannopoulos, Dennis Cokkinos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2016)
Retrolental Fibroplasia: Efficacy of Vitamin E in a Double-Blind Clinical Study of Preterm Infants
Authors: Helen Mintz Hittner, Louis B. Godio, Arnold J. Rudolph, James M. Adams, Joseph A. Garcia-Prats, Zvi Friedman, Judith A. Kautz, William A. Monaco
Journal: New England Journal of Medicine (1981)

We performed a double-blind study in 101 preterm infants who weighed less than or equal to 1500 g at birth, who had respiratory distress, and who survived for at least four weeks, to evaluate the efficacy of oral vitamin E in preventing the development of retrolental fibroplasia. Weekly indirect ophthalmologic examinations begun when the infants were three weeks old revealed a significant decrease in the incidence of retrolental fibroplasia greater than or equal to Grade III (P less than 0.03) and greater than or equal to Grade II (P less than 0.05) (McCormick classification) in the 50 infants given 100 mg of vitamin E per kilogram of body weight per day as compared with 51 given 5 mg per kilogram per day (controls). When multivariate analysis was applied to the controls, five risk factors were identified: gestational age, level and duration of administration oxygen, intraventricular hemorrhage, sepsis, and birth weight. When multivariate analysis was applied to both control and treatment groups, the severity of retrolental fibroplasia was found to be significantly reduced in infants given 100 mg of vitamin E (P = 0.012).
Prevalence and Risk Factors of Hepatitis B Infection in Pregnant Women at the Prenatal Clinic of The University of the Philippines – Philippine General Hospital
Authors: Gian Carlo A. Carpio, Aubrey Q. Taguba, Lana Corinne Q. Tan, Janus P. Ong, Ma. Lourdes O. Daez
Journal: Clinical Gastroenterology and Hepatology (2015)
Cellular Infiltrate Induced By Bites From The Tick Amblyomma Americanum In Subjects With Or Without IgE To Galactose-Alpha-1,3-Galactose (Alpha-gal)
Authors: Nikhila Schroeder, Jake Eccles, Erin J. Klaffky, Thomas A.E. Platts-Mills
Journal: Journal of Allergy and Clinical Immunology (2014)
Abstract 3311: <i>In vivo</i> selection of S. <i>typhimurium</i> A1-R enhanced tumor-targeting variants.
Authors: Fuminori Uehara, Yong Zhang, Yasunori Tome, Hiroki Maehara, Fuminori Kanaya, Robert M. Hoffman, Ming Zhao
Journal: Cancer Research (2013)

Abstract The S. typhimurium A1-R mutant (A1-R), which is auxotrophic for leu-arg, and selected for high antitumor virulence, has been previously shown to be effective as monotherapy against human breast, prostate, pancreatic, and fibrosarcoma tumors that have been orthotopically implanted in nude mice. In the present study, we generated an enhanced tumor-targeting S. typhimurium variant using in vivo selection. Dual-color murine mammary tumor (MMT) cells expressing green fluorescent protein (GFP) in the nucleus and red fluorescent protein (RFP) in the cytoplasm were injected (1 × 106 cells) in both flanks of 4-week-old female nude mice. Seven days after tumor implantation, A1-R bacteria were injected (1 × 107 cfu iv). Five days after injection, the tumors were harvested and minced. The bacteria which invaded the tumor were isolated and seeded on LB agar. After overnight incubation, colonies were picked and purified and termed A1-R1. The procedure was repeated with A1-R1 to obtain A1-R2. To determine the efficacy of the new bacterial variants, MMT-dual cells were seeded onto the 6-well plates. After 48 hours incubation, A1-R, A1-R1, and A1-R2 (1 × 108 cfu/well) were added to each plate. After 0, 24, 48, 72, 96 hours incubation, each plate was observed by confocal microscopy. Compared with A1-R, the infection rate of cancer cells by A1-R1 and A1-R2 was increased. The A1-R1 and A1-R2 variant bacteria generated in vivo selection show promise for improved bacterial targeting in vivo. Citation Format: Fuminori Uehara, Yong Zhang, Yasunori Tome, Hiroki Maehara, Fuminori Kanaya, Robert M. Hoffman, Ming Zhao. In vivo selection of S. typhimurium A1-R enhanced tumor-targeting variants. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3311. doi:10.1158/1538-7445.AM2013-3311
Assessment of the Likelihood of Invasive Breast Cancer When Core Needle Biopsy Shows DCIS.
Authors: E. Kurniawan, A. Rose, A. Mou, M. Buchanan, J. Collins, M. Wong, J. Miller, G. Mann
Journal: Cancer Research (2009)

Abstract Background: Ductal carcinoma in-situ (DCIS) on core needle biopsy (CNB) may be associated with a final diagnosis of invasive cancer (IC). As patients with IC need axillary assessment, those at risk of upstaging may be appropriate for sentinel node biopsy (SNB) at initial surgery, preventing the need for re-operation. We assessed this risk using pre-operative factors to develop a management algorithm.Materials and Methods: All patients whose CNB showed DCIS or DCIS with microinvasion (DCISm) from a single population-based breast screening program in Australia between 1994 and 2006 were studied. Medical records were reviewed for demographic, radiologic, clinical and pathologic data.Results: 11 of 15 DCISm cases (73.3%) and 65 of 375 DCIS cases (17.3%) were upstaged to IC. Microinvasion on CNB overwhelmingly predicted presence of frank invasive cancer. For cases of DCIS, multivariate analysis showed that (1) palpability (p=0.009), (2) large mammographic size ≥20mm (p=0.001) and (3) prolonged screening interval ≥3 years (p=0.008) were associated with upstaging. On univariate analysis, (4) non-calcific mammographic features (mass, architectural distortion or non-specific density) were significantly associated with upstaging (p=0.001). There was a trend towards upstaging in patients with high grade DCIS on CNB (p=0.07). Factors not associated with upstaging were microcalcifications (p=0.12), comedonecrosis (p=0.14), age (p=0.38) and CNB method (p=0.50). The rate of upstaging increases with the number of associated risk factors present in a patient: 8.3% in patients with no risk factors, 21.2% in those with one risk factor, 38.6% in those with two risk factors, and 52.9% in those with three risk factors. 13 patients (3.3%) had lymph node metastases.Conclusions: The risk of upstaging can be estimated using pre-operative features in patients with DCIS on CNB. We propose a management algorithm that includes SNB for DCIS patients: with microinvasion on core biopsy, with two or more predictive factors, and those with planned total mastectomy. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3111.
Clinical and Genetic Features of Ehlers–Danlos Syndrome Type IV, the Vascular Type
Authors: Melanie Pepin, Ulrike Schwarze, Andrea Superti-Furga, Peter H. Byers
Journal: New England Journal of Medicine (2000)

Ehlers–Danlos syndrome type IV, the vascular type, results from mutations in the gene for type III procollagen (COL3A1). Affected patients are at risk for arterial, bowel, and uterine rupture, but the timing of these events, their frequency, and the course of the disease are not well documented.
The Evaluation of Chest Pain in Women
Authors: Pamela S. Douglas, Geoffrey S. Ginsburg
Journal: New England Journal of Medicine (1996)

The evaluation of chest pain is a critical step in the care of women with heart disease. It is a point at which women are likely to be treated differently from men,16 especially when the diagnosis has not been established. Among patients known to have coronary artery disease, differences in the care given the two sexes are much less sharp. Physicians may be puzzled about how to incorporate into clinical care new data on different patterns of treatment for men and women.In the study of coronary heart disease, women have often been excluded from clinical trials or studied . . .